[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549948":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":45,"responsibleParty":116,"collaborators":63,"id":118,"slug":119,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":63,"eligibilityCriteria":124,"healthyVolunteers":120,"sex":125,"minAge":126,"maxAge":63,"enrollmentInfo":127,"targetDuration":63,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":48,"whyStopped":63,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Ottawa Hospital Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Arm: Colchicine","EXPERIMENTAL","Colchicine 0.5 mg po once daily for 180 days. After the Day - 180 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.",[13],"Drug: Colchicine 0.5 mg po",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Arm : Placebo","PLACEBO_COMPARATOR","Placebo 0.5 mg po once daily for 180 days. After the Day - 180 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.",[19],"Drug: Placebo 0.5 mg po",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Colchicine 0.5 mg po","Colchicine 0.5 mg po once daily for 180 days.",[9],[27],"Myinfla tablet 0.5 mg po daily",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo 0.5 mg po","Placebo 0.5 mg po once daily for 180 days.",[15],[33],"Placebo 0.5 mg po daily",[35],{"name":36,"affiliation":37,"role":38},"Marc Carrier, MD,MSc,FRCPC","Ottawa Hospital Research Institute \u002F Division of Hematology- The Ottawa Hospital","PRINCIPAL_INVESTIGATOR",[40],{"name":36,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","6137378899","Ext. 73668","mcarrier@toh.ca",[46,66,83,101],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"The Ottawa Hospital General Campus","RECRUITING","Ottawa","Ontario","K1H 8L6","Canada","CA",{"type":55,"coordinates":56},"Point",[57,58],-75.69812,45.41117,{"lat":58,"lon":57},[61,65],{"name":62,"role":41,"phone":63,"phoneExt":63,"email":64},"Erica Brown",null,"ericabrown@ohri.ca",{"name":36,"role":38,"phone":63,"phoneExt":63,"email":63},{"facility":67,"status":48,"city":68,"state":50,"zip":69,"country":52,"countryCode":53,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Windsor Regional Hospital","Windsor","N8W2X3",{"type":55,"coordinates":71},[72,73],-83.01654,42.30008,{"lat":73,"lon":72},[76,81],{"name":77,"role":41,"phone":78,"phoneExt":79,"email":80},"Vivian Alie","519-253-3191","58642","Vivian.Alie@wrh.on.ca",{"name":82,"role":38,"phone":63,"phoneExt":63,"email":63},"Andrea Cervi, MD, MSc, FRCPC,",{"facility":84,"status":48,"city":85,"state":86,"zip":87,"country":52,"countryCode":53,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Centre de recherche du Centre hospitalier de l'Université de Montréal","Montreal","Quebec","H2X 0A9",{"type":55,"coordinates":89},[90,91],-73.58781,45.50884,{"lat":91,"lon":90},[94,99],{"name":95,"role":41,"phone":96,"phoneExt":97,"email":98},"Amélie Martin","514-890-8000","31541","amelie.martin.chum@ssss.gouv.qc.ca",{"name":100,"role":38,"phone":63,"phoneExt":63,"email":63},"Emmanuelle Duceppe, MD,PhD,FRCPC",{"facility":102,"status":103,"city":85,"state":86,"zip":104,"country":52,"countryCode":53,"cosmosGeoPoint":105,"geoPoint":107,"contacts":108},"The Sir Mortimer B. Davis Jewish General Hospital","NOT_YET_RECRUITING","H3T 1E2",{"type":55,"coordinates":106},[90,91],{"lat":91,"lon":90},[109,114],{"name":110,"role":41,"phone":111,"phoneExt":112,"email":113},"Stephanie Scala","514-340-8222","22178","Stephanie.Scala@ladydavis.ca",{"name":115,"role":38,"phone":63,"phoneExt":63,"email":63},"Susan Kahn, MD,MSc,FRCPC",{"type":117,"investigatorFullName":63,"investigatorTitle":63,"investigatorAffiliation":63,"oldNameTitle":63,"oldOrganization":63},"SPONSOR","100549948","phase-3-colchicine-to-quench-the-inflammatory-response-after-deep-vein-thrombosis-the-conquer-dvt-pilot-trial-100549948",false,"NCT06440694","Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)","Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis: A Randomized Controlled Pilot Trial","Inclusion Criteria:\n\n* Consenting patients 18 years of age or older with a first, acute, symptomatic proximal (popliteal vein or more proximal) objectively confirmed DVT of the lower extremity will be eligible to participate in the study.\n\nExclusion Criteria:\n\n1. History of an allergic reaction or significant sensitivity to colchicine.\n2. Requirement of colchicine for other indications.\n3. Active or chronic diarrhea, or documented inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis), collagenous colitis or irritable bowel syndrome or existing blood dyscrasias.\n4. Known or suspected, recent (\\\u003C30 days) or active infections (acute or chronic).\n5. History of cirrhosis, chronic active hepatitis, or severe liver disease.\n6. Recent (\\\u003C30 days) or chronic use of systemic (oral, intravenous) immunosuppressive drugs (including but not limited to steroids, tumor necrosis factor-alpha blockers, cyclosporine).\n7. Known active cancer.\n8. Any of the following as measured within the past 1-3 months or at screening: alanine, or aspartate aminotransferase \\>3 times the upper limit of normal, total bilirubin \\>2 times the upper limit of normal and a creatinine clearance by Cockcroft-Gault formula \\\u003C30 mL\u002Fmin.\n9. Pregnancy, breast feeding or may be considering pregnancy during the study period or women of childbearing potential unwilling to use appropriate contraception during sex;\n10. The use of medication with known drug-to-drug interactions (including but not limited to erythromycin or clarithromycin).\n11. Unable or unwilling to provide consent.","ALL","18 Years",{"count":128,"type":129},150,"ESTIMATED","INTERVENTIONAL",[132],"PHASE3","This trial seeks to assess the feasibility of a full-scale, double-blind, placebo-controlled, randomized trial assessing whether low-dose colchicine (0.5 mg daily) reduces the risk of post-thrombotic syndrome (PTS) in patients with proximal lower extremity deep vein thrombosis (DVT).",[135],"Venous Thromboembolism",[137,138,139,140,141],"Proximal Lower Extremity Deep Vein Thrombosis","Randomized Trial","Colchicine","Post Thrombotic Syndrome","Inflammation","2026-07-22",{"date":144,"type":145},"2026-07-23","ACTUAL",{"date":147,"type":145},"2025-07-07",{"date":149,"type":129},"2027-12-01",{"name":5,"class":6},4]